Barclays raised the firm’s price target on Organon (OGN) to $8 from $7.50 and keeps an Underweight rating on the shares. The firm updated the company’s model post the Q4 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon to exclusively license global rights to Miudella for $27.5M
- Organon Audit Review Finds No Issues, 10-K On Track
- Organon: Hold Rating Maintained Amid Mixed Fundamentals, Governance Uncertainty, and Margin Pressures
- Organon Earnings Call Balances Stability With Rising Risks
- Midday Fly By: Cisco reports Q2 beat, Trump orders Pentagon to buy coal